Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Current Investments: 2013-2025

Historic Cash & Current Investments for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $276.2 million.

  • Amphastar Pharmaceuticals' Cash & Current Investments rose 10.27% to $276.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $966.5 million, marking a year-over-year decrease of 4.74%. This contributed to the annual value of $221.6 million for FY2024, which is 13.69% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Cash & Current Investments is $276.2 million, which was up 19.18% from $231.8 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash & Current Investments ranged from a high of $299.9 million in Q3 2023 and a low of $114.6 million during Q3 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Cash & Current Investments had a median value of $236.9 million in 2025 and averaged $239.7 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Cash & Current Investments spiked by 67.07% in 2021 and then declined by 18.19% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $136.7 million in 2021, then grew by 28.60% to $175.8 million in 2022, then surged by 46.11% to $256.8 million in 2023, then dropped by 13.69% to $221.6 million in 2024, then increased by 10.27% to $276.2 million in 2025.
  • Its last three reported values are $276.2 million in Q3 2025, $231.8 million for Q2 2025, and $236.9 million during Q1 2025.